ASND – ascendis pharma a/s - ordinary share (US:NASDAQ)
Stock Stats
News
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
Form 8-A12B/A Ascendis Pharma A/S
Form 6-K Ascendis Pharma A/S For: Apr 20
Form 6-K Ascendis Pharma A/S For: Apr 15
Form 6-K Ascendis Pharma A/S For: Apr 08
Form 6-K Ascendis Pharma A/S For: Apr 08
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.